Ion sequential therapy aligned with pathological changes enhances cardiac function after myocardial infarction Authors: Yiming Zhong, Zhaowenbin Zhang, Shixing Huang, Ao Shen, Bei Qian, Qiang Long, Zhaoxi Qi, Xiaojun He, Yecen Zhang, Lan Chang, Wangxi Hai, Xinming Wang, Zhengwei You, Qiang Zhao, Jiang Chang, Xiaofeng Ye Published: 2026 ABSTRACT SummaryMyocardial infarction (MI) induces critical trace element imbalances that exacerbate adverse ventricular remodeling. Here, we comprehensively map the spatiotemporal dynamics of zinc (Zn) and copper (Cu) ions post-MI and design a sequential Zn-Cu therapeutic regimen tailored to match staged physiological demands. This temporally controlled administration effectively modulates ion levels and significantly improves overall cardiac function, attenuating post-infarction heart failure. Mechanistically, we demonstrate that therapeutic efficacy inherently relies on the precise modulation of the core circadian rhythm gene, period circadian protein homolog 2 (PER2), which controls cellular metabolic homeostasis. To autonomously sustain this molecular regulatory mechanism and further optimize cardiomyocyte repair, we engineer a perfusable epicardial device (PerMed) that maintains stable, localized ion concentrations, thereby minimizing off-target systemic effects. Ultimately, this Zn-Cu sequential therapy offers a highly targeted intervention strategy strictly aligned with the dynamic pathological microenvironment alterations emerging immediately following myocardial infarction. Introduction Trace elements are widely present in dietary minerals, and despite accounting for a mere fraction of the organism (less than 0.01%), they hold immense significance in maintaining the normal growth and development of living beings.1,2 These trace element ions are essential components of enzymes, helping attract substrate molecules and facilitating their conversion into distinct end products.3 Additionally, some ions engage in redox reactions within the body, constantly exchanging electrons to generate a continuous supply of energy essential for sustaining life.4 Other ions contribute to maintaining the structural integrity of biomolecules,4 while still others regulate diverse biological processes, trigger cellular gene expression, and facilitate protein synthesis.5 Therefore, reactions involving these ions are not only integral to physiological functions but also play a role in the pathological processes of various diseases. Diseases have the potential to disrupt the delicate microenvironment of trace element ions within the human body. As early as 1956, the World Health Organization and other researchers observed notable fluctuations in serum ion levels among patients suffering from myocardial infarction (MI).6,7 Changes in this ion following a heart attack have since garnered significant attention from the scientific community. Studies have revealed that variations in serum ion concentrations can serve as valuable biological markers for assessing the prognosis of MI. Specifically, serum levels of certain ions, such as zinc (Zn) and selenium (Se), have been found to negatively correlate with the degree of apoptosis after a heart attack. This suggests that lower levels of these ions may be indicative of increased cellular death. Conversely, serum ion concentrations of copper (Cu) and iron (Fe) have exhibited a positive correlation with cardiac troponin levels, a prognostic indicator following MI. This association implies that elevated levels of these ions may be linked to improved heart function recovery and a more favorable prognosis after a heart attack.8,9 In light of these findings, some studies have emphasized the importance of maintaining serum ion concentrations through exogenous supplementation of solutions rich in these ions following MI. However, studies reveal a puzzling inconsistency on the therapeutic efficacy of such supplementation. For instance, Que et al. developed Zn ion solution and Cu ion solution and discovered that these ions can markedly enhance cardiac function in mice, rats, and Bama minipigs with MI.10,11 Xu et al. suggested that both exogenous and endogenous Zn release may play a crucial role in protecting the heart against ischemia/reperfusion injury.12 Xiao et al. discovered that Cu inhibits the transformation of fibroblasts into myofibroblasts, leading to profibrinolytic shifts and improved cardiac function.13 Conversely, studies conducted by Toshitaka et al. did not demonstrate significant therapeutic benefits of Zn ion supplementation in patients with acute MI.14 Moreover, Wang et al. postulated that Cu ions may constitute a potential risk factor for cardiovascular diseases, as their intake may induce arrhythmias, subsequently elevating the risk of heart failure.15 This divergence highlights the existence of non-trivial issues in previous treatment approaches aimed at maintaining serum ion levels after a heart attack. After thoroughly analyzing the relevant research on ion therapy, it has become evident that the majority of previous studies have concentrated on the supplementation of individual elemental ions.13,16,17 While few studies have attempted combined supplementation with multiple elemental ions, they have typically approached this by merely mixing various trace elements together, disregarding the temporal sequence of changes in these elements following MI. Furthermore, in the majority of these studies, ion therapy was delivered via the tail vein. This mode of administration leads to swift metabolism of ions through the bloodstream, followed by their excretion in urine. As a result, only a minuscule quantity of ions actually reaches the damaged region and is unable to sustain at a biologically active concentration over an extended time span.10,11 Remarkably, among the 19 essential trace elements present in the human body, Zn and Cu ions exhibit the most pronounced and opposing trends in serum levels before and after MI. Specifically, within the initial 24 h after infarction, Zn ion concentrations undergo a sharp decline and remain low for subsequent 4 to 5 days before gradually rising again. Conversely, after MI, the levels of Cu ions gradually increased until it began to decrease on the 7th day.4,18,19,20 This shift is primarily influenced by two key factors. First, after MI, reactive oxygen species (ROS) and inflammatory cytokines accumulate significantly in the affected area. Zn, as a cofactor for various antioxidant enzymes (including glutathione peroxidase, metallothionein, and superoxide dismutase), tightly binds to these enzymes, resulting in rapid depletion of systemic free Zn ions.21,22,23 Second, following myocardial ischemia, formation of new blood vessels is crucial in the myocardium, thereby necessitating the mobilization of large quantities of Cu ions into the nuclei of endothelial cells. This process activates hypoxia-inducible factor 1 (HIF-1) and promotes angiogenesis.24 Consequently, Cu transporters such as Ctr1 and ATP7A initiate the transport of Cu ions into the bloodstream for delivery to the site of myocardial ischemia.25 However, as inflammation intensifies, excessive accumulation of free Cu ions in the human body can trigger oxidative stress. To counteract this, the body’s Cu homeostasis mechanism gradually adjusts the concentration of Cu ions. Cu homeostasis is crucial for maintaining numerous key physiological functions in organisms, including mitochondrial energy production, redox homeostasis, tyrosine and neurotransmitter metabolism, and extracellular matrix remodeling. Numerous studies have demonstrated that Cu deficiency can lead to increased collagen deposition and myocardial fibrosis, subsequently impairing the antioxidant defense system, increasing susceptibility to oxidative stress, and adversely affecting angiogenesis. Conversely, cellular Cu overload can activate apoptotic pathways.26 Consequently, the Cu ion concentration can reach an optimal level, conducive to angiogenesis, only at specific time points of Cu homeostasis. Unfortunately, this ideal Cu ion concentration state is difficult to maintain, as free Cu ions are rapidly absorbed in the blood and consumed by endothelial cells.24,27,28,29 Furthermore, previous studies have primarily focused on observing changes in serum trace element ions before and after MI, while overlooking alterations in trace element ions within the myocardial tissue itself. Nevertheless, changes in ion patterns within the myocardial tissue may provide a more direct reflection of the pathological state of myocardium and are thus more suitable as a foundation for ion therapy. Based on the aforementioned research, we identified three key issues with current ion-based treatments for MI: first, there is an overemphasis on the replenishment of single elemental ions; second, the temporal sequence of changes in different trace elemental ions is not considered; and third, there is lack of analysis of the in situ changes in trace elemental ions in the myocardial tissue. To address these issues, we hypothesized that if an in situ sequential ion replenishment scheme can be designed based on the changes in trace elemental ions within the myocardial tissue before and after MI, it may optimize the effectiveness of ion therapy. To test this hypothesis, we collected serum and infarcted tissue samples from rats with MI and performed inductively coupled plasma optical emission spectrometry to compare and analyze the changes in Zn and Cu ions. Based on the findings, we designed a sequential Zn and Cu ion replenishment scheme. To optimize the ion therapy environment, we specifically chose two typical Zn- and Cu-containing silicate bioceramics, hardystonite and cuprorivaite, to prepare Zn and Cu ion solutions. Silicate bioceramics are chosen primarily because the silicon (Si) ions they release can act as enhancers, significantly improving the biological activity of Zn and Cu ions and thereby potentially enhancing the therapeutic effect.30,31,32 Regarding the treatment strategy, we devised two intervention methods based on the pathological alterations observed in ion concentrations within the serum and myocardial tissue. First, Zn and Cu ions were administered sequentially through tail vein injection to evaluate the therapeutic efficacy of ions that mirror the pathological changes in the serum. Through this route, the ions enter the bloodstream via the tail vein and subsequently reach the infarct border zone through myocardial capillaries, thereby exerting their therapeutic effects.10,33,34 Second, we employed a perfusable multifunctional epicardial device (PerMed) to deliver sequential ion therapy directly to the region of MI in situ. This method enables ions to reach the affected region directly, thereby establishing a localized ionic microenvironment. Not only does this approach facilitate the creation of a stable ionic microenvironment, it also minimizes ionic interference with other organs. More importantly, in situ ion delivery approach using PerMed at the site of MI allows Zn and Cu ions to be maintained within the bioactive concentration range for an extended period. Finally, transcriptome sequencing analysis and in vitro experiments were performed to analyze and validate the biological mechanisms involved in sequential ion therapy for treating MI (Figure 1).Figure 1The design basis, therapeutic mechanism, and application approach of zinc-copper (Zn-Cu) ion sequential therapy for myocardial infarctionInitially, following a myocardial infarction, attention was given to the homeostatic balance of Zn and Cu ions in both the serum and the infarcted region. Through an examination of Zn and Cu ion variation patterns, a scientific rationale for Zn-Cu ion sequential therapy was formulated to address the different phased requirements of body for these trace elements after myocardial infarction. Additionally, further investigation revealed that the therapeutic mechanism of Zn-Cu ion sequential therapy involves the upregulation of the protective protein Per2, meanwhile elevating the metabolic activity of cardiomyocytes. Finally, the implementation of the PerMed device was proposed for the direct delivery of Zn-Cu ions to the infarcted area, fostering a stable ion microenvironment and presenting a cutting-edge therapeutic avenue for myocardial infarction. The design basis, therapeutic mechanism, and application approach of zinc-copper (Zn-Cu) ion sequential therapy for myocardial infarction Initially, following a myocardial infarction, attention was given to the homeostatic balance of Zn and Cu ions in both the serum and the infarcted region. Through an examination of Zn and Cu ion variation patterns, a scientific rationale for Zn-Cu ion sequential therapy was formulated to address the different phased requirements of body for these trace elements after myocardial infarction. Additionally, further investigation revealed that the therapeutic mechanism of Zn-Cu ion sequential therapy involves the upregulation of the protective protein Per2, meanwhile elevating the metabolic activity of cardiomyocytes. Finally, the implementation of the PerMed device was proposed for the direct delivery of Zn-Cu ions to the infarcted area, fostering a stable ion microenvironment and presenting a cutting-edge therapeutic avenue for myocardial infarction. Results Zn-Cu ion sequential therapy via tail vein injection enhances left ventricular function in rats with MI First, we investigated the temporal variations due to Zn and Cu ions in the serum of rats after MI. The findings indicated significant differences in the expression patterns of Zn and Cu ions. Specifically, the concentration of Zn ions decreased significantly after MI, reaching lowest levels within 24 h post-infarction and maintaining a low level from day 1 to day 7 afterward. Conversely, Cu ion levels increased immediately after MI, peaking at days 5–7, followed by a rapid decline (Figure 2A). During the process of heart failure induced by acute MI, changes in the concentrations of Zn and Cu ions in the peripheral blood may be closely related to alterations in the expression levels of relevant transporter proteins. For instance, in this study, we selected the Zn ion transporter slc39a11 and the Cu ion transporter slc31a2 for validation and found that the expression of these two transporters correlated with the alterations in Zn and Cu ion concentrations (Figures S1 and S2). Based on this temporal variation of Zn and Cu ions in rat serum, we designed an experiment to evaluate the efficacy of Zn-Cu ion sequential therapy administered via tail vein injection. For the treatments, we prepared Zn and Cu ion extraction solutions using hardystonite and cuprorivaite. Specifically, the concentration of Zn ions was 26.04 ± 3.83 μg/mL, that of Cu ions was 25.35 ± 4.57 μg/mL, and that of Si ions was 65.36 ± 3.12 and 68.21 ± 1.01 μg/mL (Table S1). All these inorganic trace element doses fall within the biologically safe concentration range.10,11 The study comprised five groups: sham, MI, Zn (Zn treatment), Cu (Cu treatment), and Zn-Cu (combined Zn-Cu treatment) (Figure 2B). The next day, after successful establishment of the MI model, we collected serum samples from all experimental groups and performed the CK-MB test, to evaluate the status of myocardial damage at the initial stage of model construction. The test results revealed no significant differences in CK-MB indicators among the experimental groups. This outcome confirmed that the degree of myocardial damage in each group was relatively similar at the initial stage of the experiment and also validated that the method employed to generate the surgical model ensured that the experimental subjects in each group had comparable initial baseline values (Figure S3). Following coronary artery occlusion in rats, the mortality rate in the MI group was at 30%. It is worth highlighting that sequential ion therapy is associated with reduction in mortality, albeit not statistically significant. Specifically, the mortality rate dropped to 17% in the Zn-Cu group, compared to 20% in the Zn group and 24% in the Cu group (Figure S4).Figure 2Therapeutic effects of Zn-Cu ion sequential therapy via tail vein injection after myocardial infarction(A) Changes of Zn and Cu ions in serum of myocardial infarction rats (n = 3).(B) Experimental grouping and study design of Zn-Cu ion sequential therapy administered via the tail vein injection in animals.(C) Representative echocardiographic images of rat hearts 28 days post-infarction.(D) Evaluation of LVEF, LVFS, LVEDd, and LVESd through echocardiography (n = 8).(E) Masson staining of heart sections on day 28 after ion therapy. Scale bars, 2 mm.(F) Statistical assessment of left ventricular wall thickness (n = 8).(G) Statistical evaluation of left ventricular fibrosis area (n = 8).(H) Wheat germ agglutinin (WGA) staining of cardiomyocytes at the myocardial infarction border zone. WGA (green), cTNT (red). Scale bars, 50 μm.(I) Determination of cross-sectional areas of cardiomyocytes at the infarcted border zone (n = 6). ⋇⋇⋇p < 0.001, ⋇⋇p < 0.01, and ⋇p < 0.05 compared with Zn-Cu group; ∗∗∗p < 0.001, ∗∗p < 0.01, and ∗p < 0.05 compared with MI group; ###p < 0.001, ##p < 0.01, and #p < 0.05 compared with Zn group; &&&p < 0.001, &&p < 0.01, and &p < 0.05 compared with Cu group. All quantitative data are presented as mean ± standard deviation (SD). n represents the exact number of independent animals (rats) per group. Statistical analysis was performed using GraphPad Prism software (v.9.0). Statistical significance was determined using one-way analysis of variance (ANOVA) followed by Tukey’s post hoc test for multiple group comparisons or repeated-measures two-way ANOVA for functional measures at different time points. Therapeutic effects of Zn-Cu ion sequential therapy via tail vein injection after myocardial infarction (A) Changes of Zn and Cu ions in serum of myocardial infarction rats (n = 3). (B) Experimental grouping and study design of Zn-Cu ion sequential therapy administered via the tail vein injection in animals. (C) Representative echocardiographic images of rat hearts 28 days post-infarction. (D) Evaluation of LVEF, LVFS, LVEDd, and LVESd through echocardiography (n = 8). (E) Masson staining of heart sections on day 28 after ion therapy. Scale bars, 2 mm. (F) Statistical assessment of left ventricular wall thickness (n = 8). (G) Statistical evaluation of left ventricular fibrosis area (n = 8). (H) Wheat germ agglutinin (WGA) staining of cardiomyocytes at the myocardial infarction border zone. WGA (green), cTNT (red). Scale bars, 50 μm. (I) Determination of cross-sectional areas of cardiomyocytes at the infarcted border zone (n = 6). ⋇⋇⋇p < 0.001, ⋇⋇p < 0.01, and ⋇p < 0.05 compared with Zn-Cu group; ∗∗∗p < 0.001, ∗∗p < 0.01, and ∗p < 0.05 compared with MI group; ###p < 0.001, ##p < 0.01, and #p < 0.05 compared with Zn group; &&&p < 0.001, &&p < 0.01, and &p < 0.05 compared with Cu group. All quantitative data are presented as mean ± standard deviation (SD). n represents the exact number of independent animals (rats) per group. Statistical analysis was performed using GraphPad Prism software (v.9.0). Statistical significance was determined using one-way analysis of variance (ANOVA) followed by Tukey’s post hoc test for multiple group comparisons or repeated-measures two-way ANOVA for functional measures at different time points. To dynamically assess left ventricle function and structural changes, key parameters including LVEF, LVFS, LVEDd, and LVESd were measured. The MI group showed a significant decline in LVEF and LVFS post-MI. Similarly, the Zn and Cu groups exhibited a decreasing trend in these parameters. However, by day 28, the Zn and Cu groups showed some recovery of left ventricle function compared to the MI group. Remarkably, the Zn-Cu ion sequential therapy group exhibited better preservation of left ventricle function as early as day 14 post-MI, with significantly enhanced LVEF and LVFS at 4 weeks compared to that of the MI group. Structurally, the Zn-Cu group had notably reduced LVEDd and LVESd (Figures 2C and 2D). It is worth mentioning that reversing the ion sequence to Cu-Zn abrogated the therapeutic effect, with no discernible improvement in LVEF and LVFS on day 28 after MI (Figure S5). Zn-Cu ion sequential therapy limits left ventricular remodeling in rats with MI We further evaluated left ventricular remodeling in rats that underwent ion sequential therapy. Masson’s trichrome staining, extending from the apex to the base of the heart, showed that the initial infarct area gradually expanded in the MI group, while the expansion rate of the infarct area in the Zn-Cu ion sequential treatment group was relatively slow. However, the change in left ventricular thickness was exactly the opposite (Figures 2E–2G). Compared with the MI group, the Zn group and the Cu group also demonstrated certain therapeutic effects such as delaying infarction and increasing left ventricular thickness. To further elucidate the impact of ion therapy on left ventricular remodeling, we performed wheat germ agglutinin (WGA) staining. The results revealed that the cross-sectional area of cardiomyocytes located in the border zone was notably reduced in the Zn-Cu group compared to those in the MI, Zn, and Cu groups. Moreover, the Zn and Cu groups showed some improvement in limiting left ventricular remodeling (Figures 2H and 2I). These findings suggest that Zn-Cu ion sequential therapy via tail vein injection can effectively limit left ventricular remodeling at 28 days post-MI. Distribution of Zn and Cu ions in various organs after Zn-Cu ion sequential therapy via tail vein injection After confirming the therapeutic efficacy of Zn-Cu ion sequential therapy, we further investigated how ion concentrations changed in various organs following systemic treatment via tail vein injection. We selected days 0, 6, 14, and 28 after MI as the time points for measurement. The results indicated that Zn ion concentrations reached a peak in all organs on day 6, ranging from 2 to 4 μg/g, after three Zn ion injections on days 1, 3, and 5 post-MI. Subsequently, Zn ion levels began to decrease rapidly, returning to normal levels by day 14. Similarly, Cu ion concentrations peaked on day 14, maintaining levels of 4–6 μg/g across all organs, following four Cu ion injections on days 7, 9, 11, and 13 post-MI. Afterward, Cu ion levels also started to decline and normalized by day 28 (Figure S6). These findings suggest that the ion concentration trends in various organs, including the heart, are consistent after ion sequential therapy via tail vein injection, and ion levels rapidly decline after reaching their peak. Furthermore, to evaluate the systemic safety of the therapy, we performed H&E staining on major organs, including the lung, liver, spleen, and kidney. Histological analysis revealed no obvious inflammatory responses or structural abnormalities in the Zn-Cu ion sequential therapy group compared to MI group, confirming the high biosafety of this treatment strategy (Figure S7). Zn-Cu ion sequential therapy via tail vein injection enhances cardiac metabolic capability in rats with MI Zn-Cu ion sequential therapy administered via the tail vein has demonstrated that it could improve cardiac function and limit left ventricular remodeling within 28 days. To further elucidate the underlying mechanism of this therapeutic strategy, we performed transcriptome sequencing analysis on cardiac tissue subjected to ion sequential therapy. Key time points for this analysis were set at day 6 post-Zn ion injection and day 14 after the completion of Zn-Cu ion sequential therapy. On day 6 post-MI, transcriptome sequencing data revealed marked differential gene expression in the Zn group compared to that in the MI group. We selected the top 30 significantly upregulated and downregulated genes (Figure S8A) and performed GO enrichment analysis on these genes identified between the two groups. Compared to the MI group, genes in the Zn group were primarily enriched in biological processes related to cell division and muscle contraction. In terms of cellular components, they were predominantly associated with mitochondria and mitochondrial inner membrane. Molecular functions that were significantly enriched included identical protein binding and protein kinase binding (Figure S8B). Additionally, we performed Reactome enrichment analysis to explore pathway enrichment of differentially expressed genes. It identified top 10 pathways with the highest enrichment for both upregulated and downregulated genes, wherein upregulated genes were primarily enriched in metabolic pathways, such as pyruvate metabolism and citrate acid (TCA) cycle. Conversely, downregulated genes were enriched in pathways related to the cell cycle and mitosis (Figures S8C and S8D). These findings collectively suggest that mitochondrial function was significantly affected on day 6 after Zn ion therapy, and there was a notable modulation in the metabolic capacity of cardiomyocytes. The heatmap of sequencing results after 14 days of ion sequential therapy showed the top 30 most significantly upregulated and downregulated genes at the transcriptome level between the Zn-Cu-ion-injected group and the MI group (Figure S9A). Next, we conducted differential expression analysis of genes between the two groups. The GO analysis for total and upregulated DEGs indicated that following Zn-Cu ion sequential therapy, DEGs were strongly associated with pathways linked to mitochondrial function, including, mitochondrion, mitochondrial respiratory chain complex I, mitochondrial respiratory chain complex I assembly, and tricarboxylic cycle. Notably, GO analysis of downregulated DEGs suggested that ion sequential therapy may have an effect on the extracellular matrix (Figures 3A and S9B). Reactome enrichment analysis identified that upregulated DEGs were primarily enriched in metabolic pathways such as the citrate (TCA) cycle and respiratory electron transport. Downregulated DEGs were closely associated with loss of extracellular matrix and extracellular matrix organization (Figures 3B and 3C). These findings strongly indicate that Zn-Cu ion sequential therapy had a significant impact on the metabolic function of myocardial tissue in rats after 14 days, including notable effects on the extracellular matrix.Figure 3Zn-Cu ion sequential therapy via tail vein injection enhances cardiac metabolic capability in myocardial infarction rats(A) GO enrichment analysis of upregulated differentially expressed genes (DEGs) comparing the Zn-Cu 14-day group to the MI 14-day group.(B) Top 10 Reactome enrichment analysis results for upregulated differentially expressed genes in the Zn-Cu 14-day group versus the MI 14-day group.(C) Top 10 Reactome enrichment analysis results for downregulated differentially expressed genes in the Zn-Cu 14-day group compared to the MI 14-day group.(D) The comparative metabolic ratios of 69 differential metabolites between the Zn-Cu ion sequential group and the MI group over 14 days.(E) A heatmap illustrating the differential metabolites between the Zn-Cu ion sequential group and the MI group over 14 days.(F) PET-CT analysis using a 17-segment heart model on day 28.(G) Quantification of SUV of 17-segment heart analysis via PET imaging for assessment of the regional metabolism of the heart (n = 5). ∗∗∗p < 0.001, ∗∗p < 0.01, and ∗p < 0.05 compared to the MI group; ###p < 0.001, ##p < 0.01, and #p < 0.05 compared to the Zn group; &&&p < 0.001, &&p < 0.01, and &p < 0.05 compared to the Cu group. Quantitative data in (G) are presented as mean ± SD. n represents the exact number of independent animals (rats) per group. Statistical analysis was performed using GraphPad Prism software (v.9.0). Statistical significance was determined using one-way ANOVA followed by Tukey’s post hoc test. Zn-Cu ion sequential therapy via tail vein injection enhances cardiac metabolic capability in myocardial infarction rats (A) GO enrichment analysis of upregulated differentially expressed genes (DEGs) comparing the Zn-Cu 14-day group to the MI 14-day group. (B) Top 10 Reactome enrichment analysis results for upregulated differentially expressed genes in the Zn-Cu 14-day group versus the MI 14-day group. (C) Top 10 Reactome enrichment analysis results for downregulated differentially expressed genes in the Zn-Cu 14-day group compared to the MI 14-day group. (D) The comparative metabolic ratios of 69 differential metabolites between the Zn-Cu ion sequential group and the MI group over 14 days. (E) A heatmap illustrating the differential metabolites between the Zn-Cu ion sequential group and the MI group over 14 days. (F) PET-CT analysis using a 17-segment heart model on day 28. (G) Quantification of SUV of 17-segment heart analysis via PET imaging for assessment of the regional metabolism of the heart (n = 5). ∗∗∗p < 0.001, ∗∗p < 0.01, and ∗p < 0.05 compared to the MI group; ###p < 0.001, ##p < 0.01, and #p < 0.05 compared to the Zn group; &&&p < 0.001, &&p < 0.01, and &p < 0.05 compared to the Cu group. Quantitative data in (G) are presented as mean ± SD. n represents the exact number of independent animals (rats) per group. Statistical analysis was performed using GraphPad Prism software (v.9.0). Statistical significance was determined using one-way ANOVA followed by Tukey’s post hoc test. Given that the transcriptome sequencing results of Zn-Cu ion sequential therapy on both day 6 and day 14 time points revealed significant effects on the metabolic capacity of cardiomyocytes, we subsequently performed metabolome profiling on the tissue from the infarcted border area that had undergone 14 days of treatment. This metabolomic analysis was carried out to further elucidate the regulatory role of Zn-Cu ion sequential therapy on the metabolic capacity of cardiomyocytes. The principal-component analysis revealed a distinct separation between the Zn-Cu ion sequential therapy group and the MI group (Figures S10A and S10B). The results identified 41 upregulated and 28 downregulated metabolite abundance between the two groups (Figure S10C). Additionally, we observed that myocardial tissue treated with Zn-Cu ion sequential therapy exhibited notably enhanced lipid metabolism, accompanied by a decrease in the production of certain carbohydrate metabolites (Figures 3D, 3E, S10D, and S11; Data S1 and S2). To validate the effect of Zn-Cu ion sequential therapy on the metabolic capacity of cardiac tissue in the infarcted region, as indicated by transcriptome and metabolome analyses, we performed PET-CT. The results revealed that in comparison to the MI group, the infarct size diminished in both the Zn and the Cu groups. Notably, the sequential Zn-Cu therapy group exhibited the highest cardiometabolic capacity (Figure S12). Furthermore, 17-segment analysis of cardiac PET-CT images, wherein the myocardial tissue was subdivided into the standardized 17-segment model for regional metabolic assessment, provided substantial evidence of the notable effects of sequential Zn-Cu therapy in enhancing cardiomyocyte metabolism (Figures 3F and 3G). Regulatory effects of Zn-Cu ion sequential therapy on myocardial angiogenesis and collagen deposition To explore the effects of ion sequential therapy, administered via the tail vein, on angiogenesis in the infarcted and border zones of the myocardium, we performed immunofluorescence for dual-staining of markers of vascular endothelium (CD31, red) and vascular adventitial smooth muscle (α-SMA, green). The results indicated that in comparison to the MI group, both the Zn and the Cu groups demonstrated increased neovascularization in the infarcted and border zones. Notably, the sequential Zn-Cu ion therapy group showed the highest number of new blood vessels and more mature vascular structures (Figure S13). Moreover, we found that Zn-Cu ion sequential therapy improved left ventricular remodeling, and transcriptome sequencing results indicated an impact on the extracellular matrix. Subsequently, we quantified the collagen distribution and proportion in infarcted tissue through immunofluorescence and Sirius Red staining. Immunofluorescence dual-staining with collagen I (green) and collagen III (red) showed increased collagen III/collagen I ratio in the infarcted zones of both Zn and Cu groups compared to the MI group. Notably, the Zn-Cu ion sequential group demonstrated the most significant elevation. The findings from Sirius Red staining aligned with those from immunofluorescence, both indicating that Zn-Cu ion sequential therapy can increase the ratio of collagen fiber subtypes in the infarcted region, ultimately restricting left ventricular remodeling 28 days after MI (Figure S14). Zn-Cu ion sequential therapy induced upregulation of Per2 expression protects cardiac tissue At 14 days post-MI, we performed transcriptome sequencing to analyze differentially expressed genes in the Zn, Cu, and Zn-Cu groups compared to those in the MI group using Venn diagrams. This analysis revealed changes of 31, 269, and 1,331 genes, respectively. Remarkably, seven core genes (Aldh1a3, Arsi, Fkbp5, Fmo2, Hif3a, Per2, and Zbtb16) were consistently regulated in all three treatment groups. Among these, Per2 was particularly noteworthy, as it showed a significant upregulation in every stage of Zn and Cu ion therapy, prompting us to investigate it further (Figure 4A).Figure 4Investigation of Zn-Cu ion sequential therapy mechanism in myocardial infarction(A) Venn diagram analysis of differentially expressed genes after 14 days of tail vein ion therapy.(B–D) Temporal trends of mRNA levels for Per2 (B), Bmal1 (C), and Cry1 (D) genes in infarcted tissue post-myocardial infarction (n = 3). ∗∗∗p < 0.001, ∗∗p < 0.01, and ∗p < 0.05 vs. day 0 group.(E and F) Per2 protein expression and quantification in infarcted myocardium after 6 days of ion therapy, comparing MI and Zn groups (n = 4). ∗∗∗p < 0.001, ∗∗p < 0.01, and ∗p < 0.05 vs. MI group.(G and H) Per2 protein expression and quantification in infarcted myocardium after 14 days of ion therapy, comparing MI, Zn, Cu, and Zn-Cu combination groups (n = 4).(I) Representative immunohistochemical staining images of Per2 in infarcted zone after 14 days of ion therapy for each treatment group. Scale bars, 50 μm.(J) Quantification of immunohistochemical staining H score to evaluate the expression of Per2 protein in the infarcted zone after ion therapy in different groups. ∗∗∗p < 0.001, ∗∗p < 0.01, and ∗p < 0.05 vs. MI group; ###p < 0.001, ##p < 0.01, and #p < 0.05 compared to the Zn group; &&&p < 0.001, &&p < 0.01, and &p < 0.05 compared to the Cu group. All quantitative data are presented as mean ± SD. n represents the exact number of independent animals (rats) per group. Statistical analysis was performed using GraphPad Prism software (v.9.0). Statistical significance was determined by Student’s t test for single pairwise comparisons (F) and one-way ANOVA followed by Tukey’s post hoc test for multiple group comparisons (B, C, D, H, J). Investigation of Zn-Cu ion sequential therapy mechanism in myocardial infarction (A) Venn diagram analysis of differentially expressed genes after 14 days of tail vein ion therapy. (B–D) Temporal trends of mRNA levels for Per2 (B), Bmal1 (C), and Cry1 (D) genes in infarcted tissue post-myocardial infarction (n = 3). ∗∗∗p < 0.001, ∗∗p < 0.01, and ∗p < 0.05 vs. day 0 group. (E and F) Per2 protein expression and quantification in infarcted myocardium after 6 days of ion therapy, comparing MI and Zn groups (n = 4). ∗∗∗p < 0.001, ∗∗p < 0.01, and ∗p < 0.05 vs. MI group. (G and H) Per2 protein expression and quantification in infarcted myocardium after 14 days of ion therapy, comparing MI, Zn, Cu, and Zn-Cu combination groups (n = 4). (I) Representative immunohistochemical staining images of Per2 in infarcted zone after 14 days of ion therapy for each treatment group. Scale bars, 50 μm. (J) Quantification of immunohistochemical staining H score to evaluate the expression of Per2 protein in the infarcted zone after ion therapy in different groups. ∗∗∗p < 0.001, ∗∗p < 0.01, and ∗p < 0.05 vs. MI group; ###p < 0.001, ##p < 0.01, and #p < 0.05 compared to the Zn group; &&&p < 0.001, &&p < 0.01, and &p < 0.05 compared to the Cu group. All quantitative data are presented as mean ± SD. n represents the exact number of independent animals (rats) per group. Statistical analysis was performed using GraphPad Prism software (v.9.0). Statistical significance was determined by Student’s t test for single pairwise comparisons (F) and one-way ANOVA followed by Tukey’s post hoc test for multiple group comparisons (B, C, D, H, J). Per2 encodes a crucial protein involved in maintaining the circadian rhythm. We examined changes in the mRNA levels of Per2 and its associated circadian rhythm genes, Bmal1 and Cry1, in infarcted tissue following MI. Our results revealed a marked decrease in Per2 expression within 24 h after infarction, which persisted in a downregulated state for 6 days before returning to normal levels after 14 days. This trend paralleled changes in Zn ion levels observed after MI. Meanwhile, the expression Bmal1 and Cry1 exhibited a persistent increase after infarction, remaining elevated until day 28 (Figures 4B–4D). Given the significant differences between the infarcted region and the border zone of cardiac tissue, we further analyzed the changes in Per2 expression in the border zone on day 14 after MI using PCR. The results indicated a high degree of similarity in the expression pattern of Per2 between the border zone and the infarcted region. Specifically, compared with the MI group, both the Zn and the Cu groups showed moderate elevation in the expression levels of Per2 in the border zone of cardiac tissue. However, the Zn-Cu ion sequential therapy group demonstrated the most prominent upregulation of Per2 (Figure S15). We further assessed protein levels in infarcted tissue after Zn-Cu ion sequential therapy. On day 6 post-infarction, the Zn group treated with Zn ions showed higher Per2 protein expression compared to that in the MI group. By day 14 post-sequential therapy, both the Zn and the Cu groups demonstrated elevated Per2 protein expression. Notably, the Zn-Cu sequential ion therapy group exhibited the highest levels of Per2 protein (Figures 4E–4H). Consistent results were observed in Per2 staining of myocardial tissue on day 14 (Figures 4I and 4J), indicating the effectiveness of ion sequential therapy in maintaining Per2 protein expression after MI. At the cellular level, we reconstructed the microenvironments characterizing distinct post-MI stages to investigate the direct cellular responses. Following the optimization of ion concentrations for cardiomyocytes (H9C2) and macrophages (RAW264.7) in vitro (Figures S16 and S17), we first sought to validate the intrinsic capacity of macrophages to internalize these ions. Western blot analysis confirmed the presence of the Zn transporter slc39a11 and the Cu transporter slc31a2 in RAW264.7 cells, substantiating the existence of functional ion-sensing machinery (Figure S18). Crucially, we observed a polarization-dependent regulation of the circadian clock gene. Both PCR and western blot analyses demonstrated that Zn ions specifically enhanced Per2 expression at the mRNA and protein levels in M1-polarized macrophages, recapitulating the cellular response during the inflammatory milieu of the acute post-MI phase. Conversely, Cu ions exhibited a robust stimulatory effect on Per2 expression in M2-polarized macrophages, aligning with the reparative microenvironment of the late post-MI phase (Figures S19 and S20). This polarization-dependent modulation in macrophages subsequently mediates the paracrine upregulation of Per2 observed in cardiomyocytes (Figures S21 and S22). To systematically validate the role of Per2 in mediating the cardioprotective effects of ion sequential therapy, we conducted both gain-of-function and loss-of-function in vivo studies. First, we utilized an adeno-associated virus (AAV9) vector to overexpress Per2 (Per2 OE) in the myocardium of infarcted rats. Echocardiographic assessment revealed that the MI Per2 OE group exhibited significantly enhanced cardiac function, with marked improvements in left ventricular ejection fraction (LVEF) and fractional shortening (LVFS) compared to the MI control group (Figures 5A and 5B). Western blot analysis confirmed the successful upregulation of Per2 protein in the MI+Per2 OE group. Concomitantly, this overexpression led to the upregulation of HIF-1α and PPARα, accompanied by the downregulation of PPARγ. These findings indicate that Per2 activation functions upstream to modulate the HIF and PPAR signaling cascades, fundamentally influencing mitochondrial function and metabolic reprogramming in the ischemic myocardial region (Figures 5C and 5D). Interestingly, rats in the Per2 inhibitor+Zn-Cu group exhibited markedly lower LVEF and LVFS values compared to the cohort receiving Zn-Cu therapy alone (Figures 5E and 5F). Therefore, to determine whether the therapeutic efficacy of the Zn-Cu ion sequential therapy strictly relies on this Per2-driven metabolic axis, we subsequently employed an AAV9-sh vector to knock down Per2 expression in cardiomyocytes prior to administering the ion treatment. Western blot results confirmed that Per2 expression was significantly suppressed in the Per2 inhibitor group, thereby effectively blocking the sequence-specific Per2 upregulation typically induced by the Zn-Cu therapy (Figures 5G and 5H). Consequently, the ability of the Zn-Cu ion sequential therapy to restore cardiac function post-MI was significantly compromised. Furthermore, at the molecular level, Per2 inhibition abrogated the therapeutic pathway alterations: the Zn-Cu-induced activation of HIF-1α and PPARα was suppressed, while PPARγ, which is typically inhibited by the ion therapy, was aberrantly upregulated (Figures 5G and 5H). Collectively, these observations demonstrate that the cardioprotective mechanism of Zn-Cu ion sequential therapy is dependent on Per2 upregulation, which subsequently drives critical metabolic reprogramming and restores mitochondrial function via the precise regulation of the HIF and PPAR signaling pathways.Figure 5Effects of Per2 overexpression and Zn-Cu therapy on cardiac function and the PPAR/HIF-1α pathway following myocardial infarction (MI)(A) Representative echocardiograms of rat hearts in the MI and Per2 overexpression (Per2 OE) groups.(B) Quantitative analysis of left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS) in the MI and Per2 OE groups (n = 6). ∗∗p < 0.01 compared with the MI group.(C) Representative western blot images showing the protein expression levels of Per2, PPARα, PPARγ, and HIF-1α in the MI and Per2 OE groups. GAPDH was used as an internal loading control.(D) Quantitative analysis of the relative protein expression levels of Per2, PPARα, PPARγ, and HIF-1α normalized to GAPDH (n = 4). ∗∗p < 0.01 and ∗∗∗p < 0.001 compared with the MI group.(E) Echocardiographic assessment of rat heart function after Per2 knockdown using AAV9-sh adenovirus and Zn-Cu ion sequential therapy. Representative echocardiograms at 28 days post-myocardial infarction.(F) Evaluation of LVEF and LVFS by echocardiography (L) (n = 6). ∗∗∗p < 0.001, ∗∗p < 0.01, and ∗p < 0.05 compared with MI group, ###p < 0.001, ##p < 0.01, and #p < 0.05 compared with Per2 inhibitor group, &&&p < 0.001, &&p < 0.01, and &p < 0.05 compared with Per2 inhibitor+Zn-Cu group.(G) Representative western blot images showing the protein expression levels of Per2, PPARα, PPARγ, and HIF-1α in the MI, Per2 Inhibitor, Per2 Inhibitor+Zn-Cu, and Zn-Cu groups.(H) Quantitative analysis of the relative protein expression levels of Per2, PPARα, PPARγ, and HIF-1α, normalized to GAPDH, for the groups (n = 4). ∗∗∗p < 0.001, ∗∗p < 0.01 compared with the MI group; ###p < 0.001, ##p < 0.01 compared with the Per2 inhibitor group; &p < 0.05 compared with the Per2 inhibitor+Zn-Cu group. All quantitative data are presented as mean ± standard deviation (SD). n represents the exact number of independent animals (rats) per group. Statistical analysis was performed using GraphPad Prism software (v.9.0). Statistical significance was determined by Student’s t test for single pairwise comparisons (B and D) and one-way ANOVA followed by Tukey’s post hoc test for multiple group comparisons (F and H). Effects of Per2 overexpression and Zn-Cu therapy on cardiac function and the PPAR/HIF-1α pathway following myocardial infarction (MI) (A) Representative echocardiograms of rat hearts in the MI and Per2 overexpression (Per2 OE) groups. (B) Quantitative analysis of left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS) in the MI and Per2 OE groups (n = 6). ∗∗p < 0.01 compared with the MI group. (C) Representative western blot images showing the protein expression levels of Per2, PPARα, PPARγ, and HIF-1α in the MI and Per2 OE groups. GAPDH was used as an internal loading control. (D) Quantitative analysis of the relative protein expression levels of Per2, PPARα, PPARγ, and HIF-1α normalized to GAPDH (n = 4). ∗∗p < 0.01 and ∗∗∗p < 0.001 compared with the MI group. (E) Echocardiographic assessment of rat heart function after Per2 knockdown using AAV9-sh adenovirus and Zn-Cu ion sequential therapy. Representative echocardiograms at 28 days post-myocardial infarction. (F) Evaluation of LVEF and LVFS by echocardiography (L) (n = 6). ∗∗∗p < 0.001, ∗∗p < 0.01, and ∗p < 0.05 compared with MI group, ###p < 0.001, ##p < 0.01, and #p < 0.05 compared with Per2 inhibitor group, &&&p < 0.001, &&p < 0.01, and &p < 0.05 compared with Per2 inhibitor+Zn-Cu group. (G) Representative western blot images showing the protein expression levels of Per2, PPARα, PPARγ, and HIF-1α in the MI, Per2 Inhibitor, Per2 Inhibitor+Zn-Cu, and Zn-Cu groups. (H) Quantitative analysis of the relative protein expression levels of Per2, PPARα, PPARγ, and HIF-1α, normalized to GAPDH, for the groups (n = 4). ∗∗∗p < 0.001, ∗∗p < 0.01 compared with the MI group; ###p < 0.001, ##p < 0.01 compared with the Per2 inhibitor group; &p < 0.05 compared with the Per2 inhibitor+Zn-Cu group. All quantitative data are presented as mean ± standard deviation (SD). n represents the exact number of independent animals (rats) per group. Statistical analysis was performed using GraphPad Prism software (v.9.0). Statistical significance was determined by Student’s t test for single pairwise comparisons (B and D) and one-way ANOVA followed by Tukey’s post hoc test for multiple group comparisons (F and H). In situ Zn-Cu ion sequential therapy using a perfusable multifunctional epicardial device after MI After observing the Zn and Cu ion concentration patterns in the serum, we adopted a systemic treatment strategy involving Zn-Cu ion sequential therapy. To further explore the impact of this therapeutic approach, we conducted an in-depth investigation into the dynamics of Zn and Cu ions in various organs of rats following MI, with a particular focus on the primary disease site and the acute infarct zone. Our examination revealed that the alterations in Zn and Cu ion levels in the myocardial tissue of the infarcted region mirrored those observed in the serum. Notably, the magnitude of changes in the concentrations of Zn and Cu ions were more marked at the infarction site, while changes in the remote myocardial region were relatively moderate, indicating more pronounced ion fluctuations at the infarction site (Figures 6A and S23). Notably, we did not observe a similar temporal variation in Zn and Cu ion concentrations in other organs (Figure S24). Given the dynamic shifts in ion concentrations within the infarcted region after MI, we hypothesized that administering Zn-Cu ion sequential therapy directly to the infarcted zone may optimize the efficacy of this therapy. To test this hypothesis, we devised an experiment using the perfusable multifunctional epicardial device (PerMed) for in situ Zn-Cu sequential ion therapy in a rat model (Video S1). The experimental group comprised sham, MI, PerMed, and PerMed+Zn-Cu (Figure 6B). The photos demonstrate that the PerMed device was fixed tightly to the heart region (Figure 6C).Figure 6In situ Zn-Cu ion sequential therapy using PerMed improves cardiac function after myocardial infarction(A) Changes of Zn and Cu ions in infarcted myocardial tissues (n = 3).(B) Experimental design and grouping for in situ Zn-Cu ion sequential therapy using PerMed after myocardial infarction.(C) PerMed device in vitro and in vivo, and Zn-Cu ion trends in the heart post in situ sequential therapy for myocardial infarction (n = 3). Scale bars, 2 mm.(D) Representative echocardiographic images of rat hearts 28 days after myocardial infarction.(E) Assessment of LVEF, LVFS, LVEDd, and LVESd by echocardiography(n = 8). ⋇⋇⋇p < 0.001, ⋇⋇p < 0.01, and ⋇p < 0.05 vs. PerMed+Zn-Cu group; ∗∗∗p < 0.001, ∗∗p < 0.01, and ∗p < 0.05 vs. MI group; ###p < 0.001, ##p < 0.01, and #p < 0.05 vs. PerMed group.(F) Masson staining of rat hearts 28 days after myocardial infarction treated with in situ Zn-Cu ion sequential therapy using PerMed. Scale bars, 2 mm.(G) Statistical evaluation of left ventricular wall thickness (n = 8).(H) Statistical assessment of left ventricular fibrosis area (n = 8).(I) Wheat germ agglutinin (WGA) staining of cardiomyocytes in the border zone. WGA (green), cTNT (red). Scale bars, 50 μm.(J) Measurement of cardiomyocyte cross-sectional area in the border zone (n = 6). ∗∗∗p < 0.001, ∗∗p < 0.01, and ∗p < 0.05 compared with MI group, ###p < 0.001, ##p < 0.01, and #p < 0.05 compared with PerMed group. All quantitative data are presented as mean ± standard deviation (SD). n represents the exact number of independent animals (rats) per group. Statistical analysis was performed using GraphPad Prism software (v.9.0). Statistical significance was determined using one-way ANOVA followed by Tukey’s post hoc test for multiple group comparisons or repeated-measures two-way ANOVA for functional measures at different time points. In situ Zn-Cu ion sequential therapy using PerMed improves cardiac function after myocardial infarction (A) Changes of Zn and Cu ions in infarcted myocardial tissues (n = 3). (B) Experimental design and grouping for in situ Zn-Cu ion sequential therapy using PerMed after myocardial infarction. (C) PerMed device in vitro and in vivo, and Zn-Cu ion trends in the heart post in situ sequential therapy for myocardial infarction (n = 3). Scale bars, 2 mm. (D) Representative echocardiographic images of rat hearts 28 days after myocardial infarction. (E) Assessment of LVEF, LVFS, LVEDd, and LVESd by echocardiography(n = 8). ⋇⋇⋇p < 0.001, ⋇⋇p < 0.01, and ⋇p < 0.05 vs. PerMed+Zn-Cu group; ∗∗∗p < 0.001, ∗∗p < 0.01, and ∗p < 0.05 vs. MI group; ###p < 0.001, ##p < 0.01, and #p < 0.05 vs. PerMed group. (F) Masson staining of rat hearts 28 days after myocardial infarction treated with in situ Zn-Cu ion sequential therapy using PerMed. Scale bars, 2 mm. (G) Statistical evaluation of left ventricular wall thickness (n = 8). (H) Statistical assessment of left ventricular fibrosis area (n = 8). (I) Wheat germ agglutinin (WGA) staining of cardiomyocytes in the border zone. WGA (green), cTNT (red). Scale bars, 50 μm. (J) Measurement of cardiomyocyte cross-sectional area in the border zone (n = 6). ∗∗∗p < 0.001, ∗∗p < 0.01, and ∗p < 0.05 compared with MI group, ###p < 0.001, ##p < 0.01, and #p < 0.05 compared with PerMed group. All quantitative data are presented as mean ± standard deviation (SD). n represents the exact number of independent animals (rats) per group. Statistical analysis was performed using GraphPad Prism software (v.9.0). Statistical significance was determined using one-way ANOVA followed by Tukey’s post hoc test for multiple group comparisons or repeated-measures two-way ANOVA for functional measures at different time points. Video S1. The PerMed was interfaced with the infarcted myocardial region of rats to carry out sequential Zn-Cu ion therapy, related to Figure 6 Video S1. The PerMed was interfaced with the infarcted myocardial region of rats to carry out sequential Zn-Cu ion therapy, related to Figure 6 We conducted an in-depth investigation into the effects of localized PerMed application on ion changes in infarcted areas and other organ tissues. Experimental results revealed that local therapy significantly reduced the required ion concentration to just one-quarter of that needed for systemic treatment. Specifically, on the sixth day following PerMed-localized Zn-Cu ion sequential therapy, the Zn ion concentration in the infarcted region reached its peak, ranging from 3 to 5 μg/g. Concurrently, the Zn ion concentration in the non-PerMed cardiac tissue also peaked on this day, with a value of approximately 2 μg/g. Notably, remote organs such as the lungs, liver, kidneys, and spleen also showed peak Zn ion concentrations on the sixth day, albeit at a lower level of 1 μg/g. As the treatment progressed, by the 14th day, we observed that Cu ion concentrations in various organs of rat had attained their maxima. Particularly in the infarcted area, where PerMed was applied, the peak Cu ion concentration was the highest, reaching 4–6 μg/g. In contrast, the peak Cu ion concentration in the non-infarcted cardiac tissue was slightly lower at 2–3 μg/g, while the remote organ tissues exhibited the lowest peak Cu ion concentration, ranging from 1–1.5 μg/g. Subsequently, the Cu ion concentrations in all organs began to decline gradually (Figures 6C and S25). These findings indicate that unlike tail vein ion sequential therapy, PerMed-localized Zn-Cu ion sequential therapy does not result in uniform “ion-rich” condition in the organs of the entire body. Instead, it creates a localized “ion pool” in the area of PerMed application. Furthermore, when compared to tail vein ion therapy, the rate of decline in ion concentration after reaching peak values differs in PerMed-localized ion therapy. Specifically, the ion concentrations in various organs decline relatively slowly following PerMed localized ion sequential therapy. Zn-Cu ion sequential therapy via PerMed application enhances cardiac function after MI Compared to the MI group and the PerMed group, the PerMed+Zn-Cu group exhibited notable LVEF and LVFS improvements as early as 7 days post-infarction, with these improvements persisting until 28 days post-infarction. Furthermore, the changes observed in LVEDd and LVESd indicated that both the PerMed group and the PerMed+Zn-Cu group had smaller diameters at 28 days post-infarction relative to the MI group, with the most pronounced reduction observed in the PerMed+Zn-Cu group (Figures 6D and 6E). Additionally, we compared the effects of tail vein Zn-Cu ion sequential therapy versus in situ PerMed+Zn-Cu sequential ion therapy after MI. The results indicated that in situ PerMed+Zn-Cu therapy was more effective in enhancing cardiac function in rats (Figure S26). Next, we evaluated the impact of locally applied Zn-Cu ion sequential therapy on left ventricular remodeling. Masson’s staining demonstrated a delay in the expansion of left ventricular fibrosis area and an increase in left ventricle thickness in the PerMed group compared to that in the MI group. Notably, the group that received local sequential Zn-Cu ion treatment through PerMed showed the most significant delay in the expansion of left ventricular fibrosis area and increase in left ventricle wall thickness (Figures 6F–6H). Additionally, upon WGA staining, both the PerMed group and the PerMed+Zn-Cu group showed a marked decrease in the cross-sectional area of cardiomyocytes at the border zone of MI, compared to the MI group. It is worth mentioning that the PerMed+Zn-Cu group had a smaller cross-sectional area of cardiomyocytes in this region compared to the PerMed group (Figures 6I and 6J). These findings strongly suggest that the PerMed+Zn-Cu group exhibited enhanced left ventricular remodeling. Regulatory effects of Zn-Cu ion sequential therapy using PerMed on cardiomyocyte metabolism, angiogenesis, and collagen deposition We subsequently evaluated the effects of locally applied Zn-Cu ion sequential therapy on cardiomyocyte metabolism, neovascularization in the infarcted zone, and collagen deposition. To assess the impact of in situ PerMed+Zn-Cu sequential ion therapy on cardiomyocyte metabolic capacity, PET-CT imaging was performed on the rats 28 days after infarction. The images demonstrated reduced left ventricular infarct sizes in both the PerMed and PerMed+Zn-Cu groups relative to the MI group, with the most pronounced reduction observed in the PerMed+Zn-Cu group. Moreover, the results showed that ion sequential therapy via PerMed enhanced the metabolic capacity of cardiomyocytes (Figures 7A and 7B). In addition, 17-segment analysis indicated that the PerMed+Zn-Cu group not only diminished the total infarct size significantly but also effectively augmented myocardial metabolic capacity at 28 days post-infarction (Figures 7C and 7D).Figure 7In situ Zn-Cu ion sequential therapy using PerMed enhances myocardial metabolism, promotes angiogenesis, and regulates collagen deposition after myocardial infarction(A) Representative PET-CT images of the heart after in situ Zn-Cu ion sequential therapy with PerMed.(B) Assessment of infarct size and cardiomyocyte metabolic capability by PET-CT on day 28 post-myocardial infarction (n = 5).(C) Representative PET-CT results on day 28 using a 17-segment heart analysis.(D) Quantification of SUV of 17-segment heart analysis via PET imaging for assessment of the regional metabolism of the heart (n = 5).(E) Immunofluorescence staining of arterioles and capillaries in the infarcted and border zones. α-SMA (green), CD31 (red), α-actinin (pink), and DAPI (blue). The scale bars, from left to right, represent 1 mm, 10 μm, and 10 μm.(F) Quantitative analysis of arterioles and capillaries immunofluorescence (n = 6).(G) Immunofluorescence staining of type III and type I collagen in infarcted zone following in situ Zn-Cu ion sequential therapy with PerMed. Scale bars, 100 μm.(H) Quantitative analysis of the type III/type I collagen ratio according to immunofluorescence images (n = 6).(I) Sirius red staining of type III and type I collagen in infarcted zone after ion therapy. Scale bars, 100 μm.(J) Quantitative analysis of the type III/type I collagen ratio according to Sirius red (n = 6). ∗∗∗p < 0.001, ∗∗p < 0.01, and ∗p < 0.05 compared with MI group and ###p < 0.001, ##p < 0.01, and #p < 0.05 compared with PerMed group. All quantitative data are presented as mean ± standard deviation (SD). n represents the exact number of independent animals (rats) per group. Statistical analysis was performed using GraphPad Prism software (v.9.0). Statistical significance was determined using one-way ANOVA followed by Tukey’s post hoc test for multiple group comparisons. In situ Zn-Cu ion sequential therapy using PerMed enhances myocardial metabolism, promotes angiogenesis, and regulates collagen deposition after myocardial infarction (A) Representative PET-CT images of the heart after in situ Zn-Cu ion sequential therapy with PerMed. (B) Assessment of infarct size and cardiomyocyte metabolic capability by PET-CT on day 28 post-myocardial infarction (n = 5). (C) Representative PET-CT results on day 28 using a 17-segment heart analysis. (D) Quantification of SUV of 17-segment heart analysis via PET imaging for assessment of the regional metabolism of the heart (n = 5). (E) Immunofluorescence staining of arterioles and capillaries in the infarcted and border zones. α-SMA (green), CD31 (red), α-actinin (pink), and DAPI (blue). The scale bars, from left to right, represent 1 mm, 10 μm, and 10 μm. (F) Quantitative analysis of arterioles and capillaries immunofluorescence (n = 6). (G) Immunofluorescence staining of type III and type I collagen in infarcted zone following in situ Zn-Cu ion sequential therapy with PerMed. Scale bars, 100 μm. (H) Quantitative analysis of the type III/type I collagen ratio according to immunofluorescence images (n = 6). (I) Sirius red staining of type III and type I collagen in infarcted zone after ion therapy. Scale bars, 100 μm. (J) Quantitative analysis of the type III/type I collagen ratio according to Sirius red (n = 6). ∗∗∗p < 0.001, ∗∗p < 0.01, and ∗p < 0.05 compared with MI group and ###p < 0.001, ##p < 0.01, and #p < 0.05 compared with PerMed group. All quantitative data are presented as mean ± standard deviation (SD). n represents the exact number of independent animals (rats) per group. Statistical analysis was performed using GraphPad Prism software (v.9.0). Statistical significance was determined using one-way ANOVA followed by Tukey’s post hoc test for multiple group comparisons. Subsequently, we performed triple-labeled immunofluorescence staining for CD31, α-SMA, and α-actin to investigate the effects of in situ PerMed+Zn-Cu sequential ion therapy on neovascularization within the infarct and border zones. The results revealed that the PerMed group exhibited a significantly higher density of new blood vessels compared to that in the MI group in both the infarct and border zones. Remarkably, the PerMed+Zn-Cu group displayed the highest density of new blood vessels, which also appeared structurally more mature (Figures 7E and 7F). Immunofluorescence analysis demonstrated that the PerMed+Zn-Cu group exhibited a significantly elevated collagen III/collagen I ratio in the infarct zone compared to the other groups. While the PerMed group also showed an increased ratio relative to the MI group, the effect was less pronounced than that in the PerMed+Zn-Cu group (Figures 7G and 7H). Sirius Red staining results were consistent with those of immunofluorescence staining, indicating that the PerMed+Zn-Cu group has the highest collagen III/collagen I ratio in the infarct zone (Figures 7I and 7J). Discussion After MI, the ion microenvironment within the infarcted region undergoes profound and persistent alterations. Considering the dynamic nature of these changes, we designed a Zn-Cu ion sequential therapy. We considered the spatial characteristics of post-infarction ion changes, with a particular focus on the infarct zone as the epicenter and driving force of the pathological process. Utilizing the PerMed device, we delivered ion sequential therapy directly to the site of MI, thereby effectively addressing the complexities of the ion microenvironment within the infarct zone. Beyond the Zn-Cu ion sequential therapy, we hypothesized that using ion chelators like EDTA to inhibit the early rise in Cu ion concentration and the late increase in Zn ion concentration following MI may also exert therapeutic effects. Given that changes in the ion microenvironment can regulate the cellular state in pathological regions, possibly through biological mechanisms different from those of ion supplementation, employing ion chelators to lower ion concentrations in pathological areas and assessing the effectiveness of this treatment approach could be another promising avenue for future exploration of MI therapy. In the early stages of MI, massive cardiomyocyte death triggers intense sterile inflammation and subsequent cascade of pathological reactions. Zn ions play a pivotal role in modulating inflammation and excess superoxide production, exerting a profound influence on early microenvironmental changes post-MI.35,36,37 Thus, early Zn ion supplementation meets the critical demand for Zn ions within the body, especially in the infarct zone. Five to seven days post-MI, the focus of ion sequential therapy shifts toward Cu ion augmentation. Cu ions exhibit potent angiogenic properties and serve as vital regulators of diverse redox reactions.38 Recent studies have revealed the significant role of Cu ions in modulating mitochondrial function and subsequently influencing metabolism, particularly lipid metabolism.39 Notably, in some recent studies, Cu-containing materials have been applied directly to the infarcted region,40,41 and results have shown therapeutic effects during the early stages of MI. However, in our study, we observed that early Cu ion administration did not seem to have a positive reparative effect on MI. We hypothesized that this could primarily be due to the fact that most of these Cu-containing materials are nanozymes, which inherently possess enzymatic activity and can effectively scavenge ROS,42 thereby offsetting the potential risk of exacerbating oxidative stress associated with early Cu ion administration. To achieve precise localized ion therapy within the heart, we leveraged the PerMed device as indicated in previous studies and applied it to our ion sequential therapy.43 As an epicardial multifunctional patch delivery system, PerMed plays a pivotal role in this treatment modality. Its advantages are multifaceted when compared to epicardial patches for local drug delivery44,45: first, as a cardiac patch, PerMed provides mechanical support to the heart post-MI, effectively mitigating excessive left ventricular dilation. This is corroborated by our histomorphological examination. Second, the cornerstone of this treatment modality is the timed supplementation of corresponding ions. PerMed seamlessly fulfills this requirement by interfacing with a drug delivery pump for medication switching. Furthermore, the efficacy of ion therapy depends on stable ion regulation. Our results indicate that even with low concentration of ion supplementation solution, a comparable ion concentration can be achieved locally as with tail vein treatment. Remarkably, the PerMed drug delivery system creates a stable and relatively high ion microenvironment within its coverage area, functioning as a drug “reservoir.” This delivery approach not only minimizes ion interference in other bodily organs but also reduces the risk of unwanted side effects. Delving deeper into the mechanisms of ion therapy, our transcriptome sequencing results revealed that Zn-Cu ion sequential therapy significantly impacted the expression of Per2 following MI. Previous research has emphasized the protective role of Per2 in the heart during myocardial ischemia in mice, with sunlight exposure shown to increase cardiac Per2 expression and mitigate myocardial ischemic damage.46 Moreover, it plays a pivotal role in maintaining early endothelial progenitor cell function in vitro and promotes angiogenesis after MI in mice, potentially explaining the enhanced neovascularization observed in the infarct zone after ion sequential therapy.46 Our sequencing results also demonstrated that Zn-Cu ion sequential therapy profoundly affects the metabolic capacity of rat cardiomyocytes. This aligns with previous studies highlighting the metabolic regulatory function of Per2 in ischemic and hypoxic environments.47,48 Specifically, Per2 adapts to hypoxic conditions by relocating to mitochondria, regulating tricarboxylic acid cycle enzyme activity, and influencing Hif-1α transcriptional expression. During myocardial ischemia, Per2 facilitates the metabolic switch from fatty acids to glucose, providing protection against ischemic injury.49 Conversely, Per2-deficient mice hearts exhibited limited carbohydrate utilization for glycolysis under ischemic and hypoxic conditions.50,51 These findings suggest that Per2 serves as a key metabolic switch in the heart’s adaptation to ischemia, promoting high-oxygen, carbohydrate-dependent metabolic pathways and playing a leading role in metabolic reprogramming. Intriguingly, Per2 also functions as a crucial regulator of circadian proteins,52 raising the question of whether our Zn-Cu ion sequential therapy, designed to align with post-MI ion microenvironment rhythms, could have deeper connections with maintaining circadian oscillations. Following MI, the circadian rhythm of mammals falls into disarray, with the dip in Per2 protein levels indicating this disruption. It primarily associates with proteins such as Clock and Bmal1, jointly forming a transcriptional-translational negative feedback loop that orchestrates the 24-h physiological cycle of organisms.53,54,55 Consequently, our research revealed that Zn-Cu ion therapy can effectively foster the relative stability of Per2, thereby aiding in the preservation of a steady circadian rhythm in mammals. Specifically, the complex formed by Per2 and Cry directly binds to the Clock/Bmal1 dimer, effectively preventing its binding to DNA and subsequently inhibiting the transcriptional activity of downstream genes, including Per1, Per2, Cry1, and Cry2, among others.53,54,55 In our study, following the severe stress of MI, Per2 expression was initially downregulated significantly, followed by gradual upregulation. This pattern suggests the presence of a negative feedback regulatory system and reflects the organism’s adaptive capacity and inherent need to preserve the circadian rhythm. Furthermore, our adopted Zn-Cu ion sequential treatment strategy can preemptively intervene at each critical stage, stabilizing Per2 expression to meet the precise regulatory demands of the mammalian circadian rhythm. In this study, we successfully simulated the immune microenvironments of early and late stages of MI at the cellular level. The early stage was typified by an inflammatory environment dominated by M1 macrophages, while the late stage shifted to a repair environment led by M2 macrophages. Experimental observations revealed that Zn ions were most effective in promoting Per2 expression in H9C2 cardiomyocytes when M1 macrophages were present, whereas Cu ions exhibited the best effect when M2 macrophages were dominant. This finding supports the superiority and possible mechanisms of ion sequential therapy. Research has shown that when macrophages undergo a transformation in their polarization phenotype, their circadian rhythm is activated, leading to increased expression of circadian-rhythm-related genes, such as Bmal1.56,57 Zn and Cu ions are well-established regulators of macrophage polarization. Zn ions can significantly induce the polarization of M2 macrophages, while Cu ions can markedly promote the polarization of M1 macrophages.58 Considering that the early-stage damaged area following MI is primarily populated by M1 macrophages, and the late stage is mainly characterized by M2 macrophages, the sequential administration of Zn-Cu ions continuously triggers macrophage activation, resulting in a shift in their polarization phenotype. Consequently, this leads to sustained elevated expression of circadian-rhythm-related genes, such as Bmal1. As a result, these macrophages further regulate the circadian rhythms of other tissue cells, including cardiomyocytes and vascular endothelial cells, through intercellular signaling pathways and other mechanisms. This enhances cellular vitality and thus significantly facilitates the repair of MI.59,60 Following the onset of MI, the infarcted region experiences severe energy deprivation in cardiomyocytes due to ischemia and hypoxia, ultimately leading to cell death.61 However, during anaerobic conditions, the metabolic switch from lipid to glucose can provide immediate energy for dying cardiomyocytes.62,63 In this study, transcriptomic and metabolomic analyses revealed that Zn-Cu ion sequential therapy significantly enhanced lipid metabolism, thereby promoting a rapid transition in the metabolic pattern from lipid to glucose. Therefore, we hypothesize that this metabolic shift, by providing energy to cardiomyocytes during the transition, may be one of the important mechanisms for myocardial protection. Moreover, the primary biological mechanisms by which Per2 promotes myocardial repair after MI may involve the regulation of mitochondrial function via the PPARα signaling pathway and the modulation of metabolic reprogramming through the HIF signaling pathway, thereby protecting cardiomyocytes.51,64 Moreover, considering that Per2 may regulate mitochondrial function and metabolic reprogramming through multiple other mechanisms and interact with the ion microenvironment formed by Zn and Cu ions, elucidating the specific biological mechanisms of the ion microenvironment-circadian rhythm-myocardial repair axis is a research direction worthy of in-depth exploration. Our study introduces a therapeutic strategy for MI, the Zn-Cu ion sequential therapy, tailored to the dynamic shifts in the ion microenvironment that occur post-MI. The crux of this approach is the modulation of Per2 protein expression, a key component of the circadian Clock, to effectively enhance cardiac recovery after infarction. By carefully managing Per2 levels, we can foster a more conducive environment for damaged cardiomyocyte repair. Additionally, our innovative use of the PerMed device establishes a stable ion microenvironment “reservoir” within the infarcted area. This design allows for precise spatiotemporal regulation of ion concentration and balance, thereby facilitating cardiomyocyte repair and regeneration, ultimately leading to improved cardiac function in patients. We firmly believe that the innovative strategies presented in this study, which include designing therapeutic drugs/materials tailored to the dynamic changes in the pathological microenvironment of the disease, may provide insights into this field. In other words, this ion therapy, which is designed based on pathological changes, may be applicable in exploring other trace element ion therapy models, and is worthy of further investigation. Limitations of the study Although our MI model demonstrates the therapeutic efficacy of sequential Zn-Cu delivery, it cannot fully recapitulate human ischemic heart disease. Rodent models lack human hemodynamic characteristics and the complex clinical comorbidities (e.g., aging and diabetes) that alter baseline inflammatory and regenerative responses. Technologically, real-time quantification of in vivo spatiotemporal ion release within the perfused myocardium remains unfeasible; thus, our kinetic profiles rely on in vitro and ex vivo approximations. Furthermore, while macrophage polarization and endothelial cell proliferation drive the observed cardiac repair, the pleiotropic nature of transition metals precludes ruling out secondary effects on other resident cells, such as cardiac fibroblasts. Future translational efforts require longitudinal studies in large animal models (e.g., porcine) to evaluate biomechanical compatibility. Additionally, integrating single-cell RNA sequencing and long-term pharmacokinetic analyses is essential to systematically elucidate the modulated molecular networks and verify chronic systemic biosafety. Furthermore, this proof-of-concept study was conducted exclusively on male rats to minimize hormonal variability. Consequently, the influence of sex on the efficacy of the Zn-Cu ion sequential therapy remains uninvestigated. Future studies incorporating female models are essential to determine whether sex-dependent differences exist in Per2-mediated myocardial repair. Resource availability Lead contact Further information and requests for resources, please reach out to the lead contact, Xiaofeng Ye (xiaofengye@hotmail.com). Materials availability This study did not generate new unique reagents. Data and code availability •All RNA sequencing and metabolomics data have been deposited in a curated public repository recognized by the scientific community, and the link to access these data is provided in the Data Availability statement (https://www.ncbi.nlm.nih.gov/bioproject/PRJNA1224286) and (https://ngdc.cncb.ac.cn/omix/release/OMIX009060).•No custom code was generated in this study.•Any additional information required to reanalyze the data reported in this work paper is available from the lead contact upon request. •All RNA sequencing and metabolomics data have been deposited in a curated public repository recognized by the scientific community, and the link to access these data is provided in the Data Availability statement (https://www.ncbi.nlm.nih.gov/bioproject/PRJNA1224286) and (https://ngdc.cncb.ac.cn/omix/release/OMIX009060). All RNA sequencing and metabolomics data have been deposited in a curated public repository recognized by the scientific community, and the link to access these data is provided in the Data Availability statement (https://www.ncbi.nlm.nih.gov/bioproject/PRJNA1224286) and (https://ngdc.cncb.ac.cn/omix/release/OMIX009060). •No custom code was generated in this study. No custom code was generated in this study. •Any additional information required to reanalyze the data reported in this work paper is available from the lead contact upon request. Any additional information required to reanalyze the data reported in this work paper is available from the lead contact upon request. Acknowledgments This work was supported by 10.13039/100000001National Science Foundation for Distinguished Young Scholars of China (82125019), 10.13039/501100012166National Key Research and Development Program of China (2022YFA1105100), Youth Fund of the 10.13039/501100001809National Natural Science Foundation of China (82100264, 32301096, and 82070429), “Chen Guang” project supported by Shanghai Municipal Education Commission and 10.13039/501100003024Shanghai Education Development Foundation (21CGA17), Program of 10.13039/100017950Shanghai Municipal Health Commission (202140184 and 2022JC028), Program of Shanghai Academic (22S31905000 and 201409005400), 10.13039/501100004921Shanghai Jiao Tong University medical engineering cross project (YG2022ZD002), and Joint research project of Institute of Biomaterials and Regenerative Medicine, School of Medicine, 10.13039/501100004921Shanghai Jiao Tong University (2022LHA10). We express our gratitude to Shanghai Luming Biotechnology Co., Ltd. for their valuable assistance with metabolic profiling. Author contributions Y.Z., Z.Z., and S.H. contributed equally to this work. Y. Zhong, Z.Z., S.H., Z.Y., J.C., and X.Y. conceived the project and designed the experiments. Y. Zhong, Z.Z., S.H., A.S., B.Q., Q.L., Z.Q., X.H., Y. Zhang, L.C., W.H., and X.W. performed the experimental investigations and methodology. Y. Zhong and Z.Z. wrote the original draft. Z.Y., Q.Z., J.C., and X.Y. supervised the overall project. Q.Z. and X.Y. acquired funding. All authors reviewed and approved the final manuscript. Declaration of interests The authors declare no competing interests. STAR★Methods Key resources table REAGENT or RESOURCESOURCEIDENTIFIERAntibodiesAnti-CD31AbcamCat# ab64543; RRID:AB_1141558Anti-α-SMAAbcamCat# ab5694; RRID:AB_2223021Anti-α-actininSigmaCat# A7811; RRID:AB_476766Anti-Collagen IAbcamCat# ab270993; RRID:AB_2927551Anti-Collagen IIIAbcamCat# ab184993; RRID:AB_2895112Anti-PPARαAbcamCat# ab227074; RRID:AB_3083737Anti-PPARγAbcamCat# ab45036; RRID:AB_1603934Anti-HIF-1αAbcamCat# ab179483; RRID:AB_2732807Anti-Per2Thermo FisherCat# PA5-89045; RRID:AB_2805317Chemicals, peptides, and recombinant proteinsZn-containing mineral (hardystonite)Shanghai Institute of Ceramics, Chinese Academy of SciencesN/ACu-containing mineral (cuprorivaite)Shanghai Institute of Ceramics, Chinese Academy of SciencesN/APerMedDonghua UniversityN/ARadioimmunoprecipitation assay (RIPA) bufferSigma-AldrichCat# R0278TRIzol solutionInvitrogenCat# 15596026Lipopolysaccharide (LPS)Sigma-AldrichCat# L2630Interleukin-4 (IL-4)PeproTechCat# 214-14Critical commercial assaysPrime Script RT Master MixTaKaRa CorporationCat# RR036ABicinchoninic acid (BCA) protein assay kitThermo FisherCat# 23225Deposited dataRNA sequencing dataNCBI BioProjectPRJNA1224286Metabolomics dataNational Genomics Data Center (NGDC) OMIXOMIX009060Experimental models: cell linesH9C2 cells (Cardiomyocytes)Cell Bank of the Chinese Academy of SciencesCat# SCSP-5211Raw264.7 macrophagesCell Bank of the Chinese Academy of SciencesCat# SCSP-5036Experimental models: organisms/strainsRat: Male Sprague-Dawley (SD) rats (180–200 g)Laboratory Animal Care Facility of Shanghai Jiao Tong University School of MedicineN/AOligonucleotidesPCR Primers (Per2, Bmal1, Cry1, Slc39a11, Slc31a2, GAPDH)This paperTable S3Software and algorithmsImageJ softwareMedia CyberneticsN/AGraphPad Prism (version 9.0)GraphPadN/ACarimas Academic softwareTurku PET CenterVersion 2.10 REAGENT or RESOURCESOURCEIDENTIFIERAntibodiesAnti-CD31AbcamCat# ab64543; RRID:AB_1141558Anti-α-SMAAbcamCat# ab5694; RRID:AB_2223021Anti-α-actininSigmaCat# A7811; RRID:AB_476766Anti-Collagen IAbcamCat# ab270993; RRID:AB_2927551Anti-Collagen IIIAbcamCat# ab184993; RRID:AB_2895112Anti-PPARαAbcamCat# ab227074; RRID:AB_3083737Anti-PPARγAbcamCat# ab45036; RRID:AB_1603934Anti-HIF-1αAbcamCat# ab179483; RRID:AB_2732807Anti-Per2Thermo FisherCat# PA5-89045; RRID:AB_2805317Chemicals, peptides, and recombinant proteinsZn-containing mineral (hardystonite)Shanghai Institute of Ceramics, Chinese Academy of SciencesN/ACu-containing mineral (cuprorivaite)Shanghai Institute of Ceramics, Chinese Academy of SciencesN/APerMedDonghua UniversityN/ARadioimmunoprecipitation assay (RIPA) bufferSigma-AldrichCat# R0278TRIzol solutionInvitrogenCat# 15596026Lipopolysaccharide (LPS)Sigma-AldrichCat# L2630Interleukin-4 (IL-4)PeproTechCat# 214-14Critical commercial assaysPrime Script RT Master MixTaKaRa CorporationCat# RR036ABicinchoninic acid (BCA) protein assay kitThermo FisherCat# 23225Deposited dataRNA sequencing dataNCBI BioProjectPRJNA1224286Metabolomics dataNational Genomics Data Center (NGDC) OMIXOMIX009060Experimental models: cell linesH9C2 cells (Cardiomyocytes)Cell Bank of the Chinese Academy of SciencesCat# SCSP-5211Raw264.7 macrophagesCell Bank of the Chinese Academy of SciencesCat# SCSP-5036Experimental models: organisms/strainsRat: Male Sprague-Dawley (SD) rats (180–200 g)Laboratory Animal Care Facility of Shanghai Jiao Tong University School of MedicineN/AOligonucleotidesPCR Primers (Per2, Bmal1, Cry1, Slc39a11, Slc31a2, GAPDH)This paperTable S3Software and algorithmsImageJ softwareMedia CyberneticsN/AGraphPad Prism (version 9.0)GraphPadN/ACarimas Academic softwareTurku PET CenterVersion 2.10 Experimental model and study participant details Animals Male Sprague-Dawley (SD) rats, aged 6 weeks, weighing 180–200 g, were obtained from the Laboratory Animal Care Facility of Shanghai Jiao Tong University School of Medicine. Animals were housed under controlled conditions with a constant temperature of 22°C–24°C and a humidity of 40–50%, with unrestricted access to sterilized water and a specialized diet. All animal procedures were performed under the strict supervision and guidance of the Experimental Animal Ethics Committee of Shanghai Jiao Tong University School (A2025057). Cell lines The rat cardiomyocyte cell line H9C2(2–1) (Cat# SCSP-5211) and the macrophage cell line RAW 264.7 (Cat# SCSP-5036) were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). Both the H9C2(2–1) and RAW 264.7 cell lines were authenticated via Short Tandem Repeat (STR) profiling and were verified as free of mycoplasma contamination by the provider prior to delivery. H9C2(2–1) and RAW 264.7 cells were passaged in standard culture medium supplemented with 10% FBS, 100 U/mL penicillin, and 100 mg/mL streptomycin. Cells were maintained under standard culture conditions in a humidified incubator at 37°C with 5% CO2. To simulate the distinct immune microenvironments present during different stages of myocardial infarction (MI), RAW 264.7 macrophages were induced to differentiate into M1 and M2 phenotypes using lipopolysaccharide (LPS) and interleukin-4 (IL-4), respectively. For in vitro co-culture experiments, H9C2 cells were cultured with the supernatants derived from these differentiated macrophages and treated with a 1/16 concentration of Zn (hardystonite) and Cu (cuprorivaite) extracts for 48 h before downstream evaluation. Method details Generation of a rat model of MI The SD rat model of MI was generated as described previously.65 Briefly, SD rats were anesthetized with 2% isoflurane via inhalation. Then, the rats were placed in a supine position on the operating pad, a rodent ventilator was connected, set at a respiratory rate of 22 breaths/min with an inhalation-to-exhalation ratio of 2:1. The surgical site was shaved and thoroughly disinfected with povidone-iodine. An incision was made carefully between the fourth and fifth ribs on the left side of the chest. Blunt dissection of the muscle tissue exposed the intercostal muscles. An eyelid retractor was used to widen the ribcage and provide clear access to the heart. The left anterior descending (LAD) coronary artery was permanently ligated using a suture (6–0 Prolene, Ethicon). Upon completing the intrathoracic procedures, the chest and skin were meticulously sutured layer by layer. The surgical site was disinfected again, anesthesia was withdrawn, and the vital signs and responses of the rats were closely monitored during recovery from anesthesia. Post surgery, the rats received routine intramuscular injections of cefazolin (100 mg/kg) for prevention of infection and buprenorphine (0.1–0.2 mg/kg) for analgesia. Furthermore, 1 day post establishment of the MI model, the collected serum was analyzed using the kit (S03023, Rayto, China), to determine the expression levels of creatine kinase-MB (CK-MB), according to the manufacturer’s instructions. This assessment was performed to evaluate the extent of myocardial injury and thereby ascertain the consistency of the MI model. Collection and processing of rat serum and organ tissues Venous blood samples were collected at day 0 as control. Following the successful establishment of SD rat model of MI, venous blood samples were collected at day 1, 3, 5, 7, 14, and 28 after surgery. The blood samples were centrifuged and the supernatant serum was collected and stored. Concurrently, various organ tissues, including the heart, lungs, liver, kidneys, and spleen, were harvested from the SD rats at the corresponding time points after MI. Determination of ion concentrations in serum and organ tissues To ascertain the ion concentrations in the serum and organ tissues of rats, a methodical experimental approach was followed. Initially, the organ tissues (heart, liver, spleen, lungs, and kidneys) were digested using a precise volume of aqua regia, a potent mixture of concentrated hydrochloric acid and nitric acid in a 3:1 volume ratio. Following thorough digestion, the resulting suspensions were centrifuged at 4000 rpm to separate the solids, and the supernatants were carefully collected. Both the supernatants and serum samples were then diluted 10-fold with deionized water to ensure analytical accuracy, yielding the final test solutions. Subsequently, inductively coupled plasma-atomic emission spectrometry was performed to analyze these prepared solutions. This state-of-the-art technique facilitated the precise measurement of zinc (Zn) and copper (Cu) ion concentrations in the solutions. The data were comprehensively analyzed to determine the specific concentrations of Zn and Cu ions in the serum and various organ tissues following MI. Preparation of Zn and Cu ion extracts The biologically active minerals containing Zn (hardystonite) and Cu (cuprorivaite), used in this study, were sourced from the Shanghai Institute of Ceramics, Chinese Academy of Sciences.31,32 To prepare the Zn and Cu ion extracts, 2g of either hardystonite or cuprorivaite powder was taken in a centrifuge tube. Subsequently, 10 mL of physiological saline or cell culture medium was added to ensure thorough wetting of the powder. The centrifuge tube was then placed in a shaking incubator maintained at 37°C and set to 300 rpm for 24 h. This step ensured the complete release of Zn or Cu ions from the powder into the solution. After incubation, the suspension was centrifuged at 5000 rpm for 10 min. The supernatant was carefully aspirated using a sterile syringe, taking precautions to avoid disturbing the sediment. Under sterile conditions, the collected supernatant was filtered through a 0.22 μm filter into a sterile centrifuge tube to eliminate any potential microbial contamination. This process yielded sterile hardystonite or cuprorivaite extract stock solution with a final concentration of 200 mg/mL. The final ion concentration of extract has been shown in Table S1. We performed prior step-by-step trials in mice and Bama miniature pig models of MI and identified this concentration of Zn and Cu ion solutions as optimal. Consequently, administration at these precise dosages maintains systemic ion homeostasis without inducing excessive trace element accumulation or impairing organ function.10,11 The sterile ion extract stock solution was stored at 4°C for future experiments. Strict adherence to sterile techniques throughout the entire preparation process ensured purity and biosafety of the extract. Sequential Zn-Cu ion therapy in SD rat model of MI For the sequential Zn-Cu ion therapy, 48 rats were used, divided into six distinct groups (sham, MI, Zn, Cu, Zn-Cu, and Cu-Zn) with eight rats in each group, which received specific treatment regimens administered through tail vein injection. In the sham group, rats were anesthetized, their hair removed, sterilized, and a simulated surgical procedure was performed that involved opening and closing the chest cavity without inducing MI. As a control, rats in the MI group received 1mL of saline solution via tail vein injection on days 1, 3, 5, 7, 9, 11, and 13 after MI. The treatment strategy for the Zn group differed, with rats receiving 1mL of Zn ion stock solution via tail vein injection on days 1, 3, and 5 after MI, followed by 1mL of normal saline solution on days 7, 9, 11, and 13. Rats in the Cu group were injected with 1mL of normal saline solution for the first 5 days after MI, and then received 1mL of Cu ion stock solution via tail vein injection on days 7, 9, 11, and 13. For the Zn-Cu group, we employed a sequential treatment approach, wherein rats received 1mL of Zn ion stock solution for the first 5 days after MI, followed by 1mL of Cu ion stock solution on days 7, 9, 11, and 13. To verify the specific effects of ion sequencing, we also established a Cu-Zn group. In this group, rats received 1mL of Cu ion stock solution via tail vein injection for the first 5 days after MI, and then switched to 1mL of Zn ion stock solution on days 7, 9, 11, and 13. All injections were carefully administered via the tail vein to ensure precise delivery of the therapeutic agents and minimize additional stress on the animals. Specifically, for each tail vein injection, a single dose of 1 mL of the respective solution was administered slowly over a duration of 1 min. Throughout the duration of the experiment, physiological status of the rats and changes in MI-related markers were monitored closely to evaluate the effectiveness and safety of the various treatment strategies. Treatment of the infarcted site in SD rats with Zn-Cu ion sequencing using PerMed Based on previous research, we designed the PerMed drug delivery device to deliver Zn-Cu ion sequencing therapy directly to the MI site.66 For this, 32 rats were used divided into four groups (sham, MI, PerMed, and PerMed+Zn-Cu) with eight rats per group. SD rats in the sham group underwent surgical procedures, including anesthesia, skin preparation, thoracotomy, and chest closure, without receiving any specific treatment. Rats in the MI group underwent permanent ligation of the left anterior descending coronary artery to induce MI. In the PerMed group, after ligating the left anterior descending coronary artery of rats and confirming successful MI modeling, we implanted the PerMed device. The implantation process involved determining the location and size of the infarcted area, fixing the assembled PerMed device onto the infarction surface using 8–0 Prolene sutures, and extending the delivery tubing system through a subcutaneous abdominal wall catheter to the back, where it was connected to an implantable osmotic pump. Over the next 14 days, we administered saline solution to the rats through the osmotic pump. After closing the chest cavity, we sutured the subcutaneous tissue and skin, allowing the rats to recover from anesthesia as they warmed up. In the PerMed+Zn-Cu group, we leveraged the implantable osmotic pump function of the PerMed device. From days 1–6 post-infarction, the pump slowly and uniformly released 3 mL of Zn ion solution (diluted to 1/4 of the stock concentration) into the infarcted area. On day 7, we replaced the osmotic pump on the backs of the rats, and a new pump delivered 4 mL of Cu ion solution (diluted to 1/4 of the stock concentration) from day 7–14 post-infarction. Finally, on day 14 post-infarction, we removed the implantable osmotic pump. Experimental animal euthanasia and sample collection Rats were euthanized at 2 p.m. on days 0, 1, 3, 6, 14, and 28 and samples were collected for pathological analysis. This predetermined sampling time was selected to ensure consistent monitoring of circadian rhythm-related proteins. Echocardiography Structural and functional assessments of the left ventricle in rats were conducted using the VEVO3100 high-resolution imaging system (Fujifilm VisualSonics, USA). Briefly, SD rats were anesthetized through inhalation of 2% isoflurane within an anesthesia chamber. Imaging was performed to acquire parasternal long-axis and parasternal short-axis views. The echocardiographic dataset predominantly comprised parameters including, left ventricular ejection fraction (LVEF), left ventricular fractional shortening (LVFS), left ventricular end-diastolic diameter (LVEDd) and left ventricular end-systolic diameter (LVESd). All measurements were determined by calculating the average values from three consecutive cardiac cycles. PET-CT and 18F-FDG PET imaging analyses SD rats were anesthetized through inhalation of 2% isoflurane and subsequently administered 0.4 mCi of 18F-FDG via the tail vein. Following injection, the rats were left undisturbed for 45 min to 1 h to allow for tissue absorption of 18F-FDG. Rat hearts were imaged using the Trans-PET BioCaliburn 700 system (Raycan Technology) in static scan mode, enabling axial, coronal, and sagittal three-dimensional visualization. For a more comprehensive analysis of the rat hearts, Carimas Academic software (Turku PET Center, Turku, Finland, version 2.10) was employed, facilitating the display of 17-segment heart images. Data was calculated based on the formula: average SUV = (average pixel value of ROI activity after attenuation correction (μCi/kg))/(injection dose [μCi]/weight [kg]). Infarct size percentage was determined using the formula: (area with SUV less than 50% of the maximum SUV area of the entire heart/total heart area) × 100%. Histological assessment After euthanasia, the rat hearts were perfused and fixed with 4% paraformaldehyde. The sections were then subjected to Masson’s, Sirius Red, wheat germ agglutinin (WGA) and immunohistochemical staining. Histological images were acquired using the panoramic digital slide scanner (MIDI II, 3D HISTECH) and subsequently analyzed using ImageJ software (Media Cybernetics). Immunofluorescence staining We performed immunofluorescence staining to evaluate angiogenesis (CD31 and α-SMA), as well as the distribution and quantity of collagen fibers (collagen I and collagen III). Following this, the sections were blocked with BSA and subsequently labeled with corresponding antibodies. Fluorescence images were acquired using the panoramic digital slide scanner (MIDI II, 3D HISTECH) and analyzed using ImageJ software (Media Cybernetics) to quantify both the fluorescence intensity and the stained area. The primary antibodies used are listed in Table S2. Transcriptome sequencing analysis of rat myocardial tissue Cardiac tissues were collected from the infarcted border regions from different groups of rats on the 6th and 14th days post-infarction. Following RNA extraction and quality verification, we performed transcriptome sequencing using the Illumina sequencing platform. Post-sequencing, we identified differentially expressed genes based on FPKM data, applying a cutoff criterion of p < 0.05 and a fold change threshold of greater than 2 or less than 0.5. We performed cluster analysis to examine the expression patterns of these genes. Additionally, we performed gene ontology (GO) enrichment and Reactome enrichment analyses to identify the biological processes and pathways associated with these genes. Metabolic profiling of rat myocardial tissue We prepared the samples by collecting heart tissues from the infarcted border regions from MI group and Zn-Cu group of rats. For GC-MS and LC-MS/MS analyses, sample preparation followed previously established procedures.67 Briefly, 30 mg of myocardial tissue was taken in a centrifuge tube along with 2 small steel balls and 600 μL of methanol-water (4:1 v/v). After incubation at −40°C, the samples were homogenized using a grinder, followed by centrifugation at 12,000 rpm for 10 min at 4°C. Then, 150 μL aliquot of the supernatant was filtered through a 0.22 μm organic phase syringe filter into an LC vial for subsequent LC-MS analysis. For GC-MS analysis, 150 μL of the supernatant was transferred to a glass derivatization vial and dried using a centrifugal concentrator. Methoxyamine hydrochloride in pyridine (80 μL) was added for oximation, followed by addition of 50 μL of BSTFA derivatization reagent and 20 μL of hexane, along with 10 internal standards. The mixture was then incubated at 70°C for 60 min and allowed to cool to room temperature for 30 min. Metabolomics analysis was performed by Shanghai Luming Biotechnology Co., Ltd. (Shanghai, China). Metabolic profiles were analyzed using the ACQUITY UPLC I-Class plus system (Waters Corporation, Milford, USA) equipped with a Q-Exactive mass spectrometer and a heated electrospray ionization source (Thermo Fisher Scientific, Waltham, MA, USA). The ACQUITY ultrahigh-performance LC HSS T3 column (2.1 × 100 mm, 1.8 μm) was used in both positive and negative modes. The binary gradient elution system consisted of (A) water containing 0.1% formic acid (v/v) and (B) acetonitrile containing 0.1% formic acid (v/v). The flow rate was set at 0.35 mL/min, and the column temperature was maintained at 45°C. Separation was achieved using the following gradient: 0.01 min, 5% B; 2.00 min, 5% B; 4.00 min, 30% B; 8.00 min, 50% B; 10.00 min, 80% B; 14.00 min, 100% B; 15.00 min, 100% B; 15.10 min and 16.00 min, 5% B. All the samples were maintained at 10°C during analysis, and the injection volume was 4 μL. The obtained samples were analyzed using GC-MS on the Agilent 8890 gas chromatograph coupled to the Agilent 5977B MSD system (Agilent Technologies, CA, USA). Separation of derivatives was achieved using the DB-5MS fused-silica capillary column (30 m × 0.25 mm × 0.25 μm, Agilent J & W Scientific, Folsom, CA, USA). Helium (>99.999%) was used as the carrier gas at a constant flow rate of 1 mL/min. The injector temperature was maintained at 260°C. The initial oven temperature was set at 60°C, held for 0.5 min, then increased to 125°C at 8°C/min, 210°C at 5°C/min, 270°C at 10°C/min, and finally 305°C at 20°C/min, where it was held for 5 min. The mass spectrometer quadrupole and ion source (electron impact) temperatures were set to 150°C. Mass spectra were acquired in full scan mode (m/z 50–500). After obtaining raw data from the dual platforms, each analysis was performed following previously described methods.68 Variable importance in projection (VIP) values obtained from the OPLS-DA model were used to rank the overall contribution of each variable to group differentiation. In addition, the Student’s two-tailed t test was performed to verify the significance of differential metabolites between groups. Differential metabolites with VIP values greater than 1.0 and p values less than 0.05 were selected. Real-time quantitative PCR and western blot analysis Total RNA was extracted from cardiac tissue and H9C2 cells using TRIzol solution. We determined the RNA concentration using the NanoDrop 1000 reader (Thermo Scientific). Subsequently, we synthesized cDNA using Prime Script RT Master Mix (TaKaRa Corporation, Japan). The Bio-Rad MyiQ Monochrome Real-Time PCR System, was used to quantify the cDNAs for the expression of stemness-related markers. To ensure data reliability, all experiments were performed in triplicate, and the results are presented as the average values. Detailed information of the primer sequences used is provided in Table S3. radioimmunoprecipitation assay buffer (Sigma-Aldrich, USA) containing protease and phosphatase inhibitors was used for protein extraction. We measured the protein concentration using the bicinchoninic acid protein assay kit (Thermo Fisher, USA). Next, we separated the proteins using sodium dodecyl sulfate–polyacrylamide gel electrophoresis and transferred them onto a polyvinylidene fluoride membrane (Millipore, MA). After blocking the membrane with phosphate-buffered saline with Tween 20 containing 5% skim milk for 2 h at room temperature, we incubated it with the primary antibody for 12 h at 4°C. Subsequently, we incubated the membrane with horseradish peroxidase-conjugated immunoglobulin G (dilution 1:5000) for 2 h at room temperature and visualized the labeled proteins using enhanced chemiluminescence reagent. To quantitatively analyze the western blotting results, we measured the grayscale using ImageJ and normalized the data against GAPDH used as the internal control. Per2 knockdown and overexpression experiment To further elucidate the critical involvement of Per2 in ion sequencing therapy, we silenced and overexpressed the gene using the AAV9 virus. The virus was delivered via tail vein injection. Per2 knockdown experiment comprised four distinct groups: MI group, MI + Per2 knockdown group, MI + Per2 knockdown + Zn-Cu group, and MI + Zn-Cu group. Per2 overexprssion experiment comprised two groups: MI group, MI + Per2 overexprssion group. Exploring the effect of sequential ion therapy in vitro To investigate the effect of sequential ion therapy in vitro, we induced differentiation of Raw264.7 macrophages into M1 and M2 phenotypes using LPS and IL-4, respectively, simulating the distinct microenvironments present during different stages of MI. Following this, supernatants from these differentiated macrophages were co-cultured with H9C2 cells. During this process, H9C2 cells were treated with a 1/16 concentration of Zn (hardystonite) and Cu (cuprorivaite) extracts. After 48 h of co-culture, RNA was collected, and the expression levels of Per2 were evaluated. Quantification and statistical analysis Statistical analysis of the data was performed using GraphPad Prism (version 9.0), and all the data are presented as mean ± standard deviation. Statistical significance is denoted by asterisks or corresponding symbols: ∗/#/& p < 0.05, ∗∗/##/&& p < 0.01, and ∗∗∗/###/&&& p < 0.001. The specific statistical tests utilized for each analysis are detailed in the respective figure legends. Student’s t test for single group pairwise comparisons, one-way analysis of variance (ANOVA) followed by Tukey’s post hoc test for multiple group comparisons, and repeated-measures two-way ANOVA for functional measures at different time points among groups were performed. Statistical significance was set at p < 0.05.